Covis pharma

Photo
10.11.2021 • News

AstraZeneca Sells COPD Drug Rights to Covis

AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma for $270 million. The transaction is expected to close in the fourth quarter of 2021.

Photo
12.10.2020 • News

Covis Buys US Biotech Amag Pharmaceuticals

Specialty pharma company Covis has agreed to buy US-based Amag Pharmaceuticals, boosting its portfolio of therapies for life-threatening conditions and chronic illnesses.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.